Global Rx Medical Food Market Accelerates Business to Gain High Revenue during 2018-2026
Medical
food is a category of products for dietary management or supportive
therapy for specific disease or medical conditions such as pulmonary
and metabolic disorders. Ingredients used in medical foods must have
generally recognized as safe (GRAS) status, which is assigned to
naturally found food materials. Medical food is different from
nutritional food, dietary supplements, and prescription drugs.
Medical food is protein-based, nutrient-based (Omega 3 fatty acids,
chelated zinc, and isoflavones), and may contain minerals and
vitamins such as folic acid and thiamine. These products are
prescribed by physicians or taken under their supervision. The U.S.
Food & Drug Administration (FDA) has classified medical foods
into four major categories namely, nutritional complete products,
nutritionally incomplete products, formulas for metabolic disorders,
and oral rehydration solutions. The U.S. FDA separately regulates
medical food category under Orphan Drug Act (1988) to ensure safety
of populace and curb presence of products falsely claiming to cure
medical conditions. Medical food does not require premarket approval,
specification as an Investigational New Drug (IND), and individual
registration with the FDA. However, they are required to support all
their health claims with proper laboratory and clinical studies.
The
global Rx medical food market was valued at US$ 14,504.6 million in
2016 and is expected to witness a robust CAGR of 7.0% over the
forecast period (2017-2025).
Some
major players operating in the Rx medical food market are Abbott
Laboratories, Danone, Mead Johnson & Company, LLC, Fresenius Kabi
AG, Nestle, Primus Pharmaceuticals, Inc., Targeted Medical Pharma,
Enzymotec ltd., AlfaSigma, and Pivotal Therapeutics.
Download
the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/909
Increasing
regulatory support and awareness about medical food among healthcare
professionals is expected to fuel market growth
The
U.S. FDA amended regulations related to formulation and marketing of
medical food in 2013, the category, which was previously ill-defined.
The new additions clarified some issues associated with marketing and
branding of medical food products. Furthermore, the U.S. FDA also
states that medical food does not require prescription, rather
requires to be consumed under the supervision of a medical
practitioner. Furthermore, the medical food market is expected to
gain traction, owing to major investments by players such as Nestlé
and Danone in research and development of medical foods along with
widening scope of applications such as chronic pain, and personalized
medicine. Medical food currently available in the market include
Axona (Accera), Limbrel, Deplin, Lofenalac, Ensure, Vasculera, and
Vascazen.
North
America is expected to hold a dominant position in the Rx medical
food market over the forecast period, followed by Europe and
Asia-Pacific
North
America accounts for the largest share in the Rx medical food market,
followed by Europe and Asia-pacific. The regulatory authorities in
North America and Europe have clearly defined and distinguished the
medical food category. The CRN will provide a common platform for
major players in the industry to work together towards the
advancement of medical food and to increase awareness about medical
food among healthcare practitioners and consumers. Nestlé has set
out a US$ 500 Mn budget to support medical food research by 2021,
which is expected to boost growth of the Rx medical food market over
the forecast period. Click To Read More On Global
Rx Medical Food Market
Comments
Post a Comment